RMAM
KERX

Raab & Moskowitz Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$3K – 430
2014
Q4 		$3K Buy
+200
New +$3.1K ﹤0.01% 431

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Raab & Moskowitz Asset Management's KERX Position: Q1 2015 in Review

Raab & Moskowitz Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2015, closing a stake of 200 shares — an estimated $3K sold.

Raab & Moskowitz Asset Management first reported a position in KERX in Q4 2014 and held it in 1 quarter. The position peaked at $3K in Q4 2014. 157 funds tracked by Wall St. Rank hold KERX as of Q1 2015.

  • Raab & Moskowitz Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Raab & Moskowitz Asset Management sold 200 Keryx Biopharmaceuticals Inc shares in Q1 2015, an estimated $3K.
  • Raab & Moskowitz Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 1 quarter.
  • Raab & Moskowitz Asset Management's Keryx Biopharmaceuticals Inc position peaked at $3K in Q4 2014.
  • 157 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2015.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2015, filed 12 May 2015.